Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Gh Research Plc (GHRS)

Gh Research Plc (GHRS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Author
3 Fast-Growing Stocks Analysts See Doubling in Price MarketBeat - Mon Nov 11, 6:14AM CST

Clinical-stage biotech firms often have massive upside potential, but much of that possible success hinges on successful trials and product launches.

IMCR : 31.59 (-3.16%)
GHRS : 9.09 (+1.34%)
NTLA : 13.97 (-7.61%)
GH Research Reports First Quarter 2022 Financial Results and Provides Business Updates Globe Newswire - Wed May 18, 2022

DUBLIN, Ireland, May 18, 2022 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming...

GHRS : 9.09 (+1.34%)
GH Research Reports Full Year 2021 Financial Results and Provides Business Updates Globe Newswire - Mon Mar 28, 2022

DUBLIN, Ireland., March 28, 2022 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming...

GHRS : 9.09 (+1.34%)
Fighting Back Against the Mental Health Crisis with Outside-the-Box Thinking and Therapeutics BayStreet.ca - Mon Mar 21, 2022

USA News Group – Before the global health crisis began at the beginning of 2020, 1 in 5 adults were receiving mental health treatment. As society emerges from the last two and a half years of disruptions,...

MOOD.CN : 0.2000 (unch)
GHRS : 9.09 (+1.34%)
MNMD : 7.76 (-7.51%)
CYBN : 11.60 (+5.45%)
JNJ : 154.00 (+1.40%)
Psychedelic Therapies Offer Hope for Mental Health Investor Brand Network - Wed Mar 2, 2022

NetworkNewsWire Editorial Coverage : Neural plasticity is instrumental in brain health, and the importance of neuroplasticity can’t be overstated. Indeed, the inability of the nervous system to change...

CYBN.NE : 16.4400 (+6.61%)
MMED.NE : 14.9000 (+9.48%)
CYBN : 11.60 (+5.45%)
CMPS : 5.04 (+3.07%)
MNMD : 7.76 (-7.51%)
ATAI : 1.6100 (+17.52%)
GHRS : 9.09 (+1.34%)
Psychedelic Therapies Offer Hope for Mental Health FinancialNewsMedia - Wed Mar 2, 2022

NetworkNewsWire Editorial Coverage   New York, NY – March 2, 2022 – Neural plasticity is instrumental in brain health, and the importance of neuroplasticity can’t be overstated. Indeed, the inability...

CYBN.NE : 16.4400 (+6.61%)
MMED.NE : 14.9000 (+9.48%)
CYBN : 11.60 (+5.45%)
CMPS : 5.04 (+3.07%)
MNMD : 7.76 (-7.51%)
ATAI : 1.6100 (+17.52%)
GHRS : 9.09 (+1.34%)
GH Research Reports Third Quarter 2021 Financial Results and Provides Business Updates Globe Newswire - Mon Dec 6, 2021

DUBLIN, Ireland, Dec. 06, 2021 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming...

GHRS : 9.09 (+1.34%)
GH Research PLC Provides Business Updates and Reports Second Quarter 2021 Financial Results Globe NewsWire - Thu Sep 23, 2021

DUBLIN, Ireland, Sept. 23, 2021 (GLOBE NEWSWIRE) -- GH Research PLC (NASDAQ: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological...

GHRS : 9.09 (+1.34%)

Barchart Exclusives

Skip the VIX, Buy This Dividend Stock to Profit from Volatility Barchart - 1 hour ago
Instead of trying to profit from market volatility through traditional means like the VIX, investors may want to consider buying shares of Cboe Global Markets, the company behind the VIX. Cboe Global Markets is well-positioned to benefit from rising demand for derivatives trading and offers a solid dividend yield. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot